Skip to main content
Erschienen in: BMC Primary Care 1/2021

Open Access 01.12.2021 | Research article

Healthcare professional-led interventions on lifestyle modifications for hypertensive patients – a systematic review and meta-analysis

verfasst von: Indre Treciokiene, Maarten Postma, Thang Nguyen, Tanja Fens, Jurgis Petkevicius, Raimondas Kubilius, Jolanta Gulbinovic, Katja Taxis

Erschienen in: BMC Primary Care | Ausgabe 1/2021

Abstract

Background

About 0.9 billion people in the world have hypertension. The mortality due to hypertension increased dramatically over the last decades. Healthcare professionals should support patients with hypertension to modify their lifestyle to decrease blood pressure, but an overview of effective lifestyle interventions is lacking. The aim of this study was to determine whether healthcare professional-led interventions on lifestyle modifications are effective in lowering blood pressure in patients with hypertension.

Methods

A systematic literature review following the PRISMA guidelines was conducted. PubMed, EMBASE and CINAHL databases were searched for randomized control trials (RCTs) of interventions on lifestyle modifications of hypertensive patients which were performed by healthcare professionals (physician, nurse, pharmacist) and which reported blood pressure measurements. Papers were reviewed by two reviewers and analysed using Cochrane software Revman 5.4. In a meta-analysis difference in systolic blood pressure (SBP), diastolic blood pressure (DBP) and the percentage of patients with controlled blood pressure (BP) was analysed.

Results

In total, 34 clinical trials reporting on 22,419 patients (mean age 58.4 years, 49.14% female, 69.9% used antihypertensive medications) were included. The mean difference SBP was − 4.41 mmHg (95% CI, − 5.52to − 3.30) and the mean difference DBP was − 1.66 mmHg (95% CI − 2.44 to − 0.88) in favor of the intervention group vs usual care. Fifty-six percent of patients achieved BP control in the intervention group vs 44% in usual care, OR = 1.87 (95% CI, 1.51 to 2.31).

Conclusion

Healthcare professional-led interventions were effective. Patients achieved almost 5 mmHg decrease of SBP and more patients achieved BP control. The results suggest that efforts are needed for widespread implementation.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12875-021-01421-z.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BP
Blood pressure
SBP
Systolic blood pressure
DBP
Diastolic blood pressure
CVD
Cardiovascular desease
CI
Confidence interval
RCT
Randomized clinical trial
cRCT
Cluster randomized clinical trial
ICC
Intracluster correlation coefficient

Background

Cardiovascular diseases (CVDs) remain the most common cause of death worldwide, causing 17.3 million (31.5%) deaths globally [1]. One of the most important risk factors to develop CVDs is hypertension [1]. Globally WHO reports suggest that 1in 5 adults had raised blood pressure [2]. In the same time period, the prevalence of hypertension among US adults of 20 years of age or older was estimated to be even 34.0% [3]. Death rates due to hypertension have increased worldwide and are associated with high costs [4]. In the U.S.A. the annual national spending on hypertension increased significantly from $58.7 billion to $109.1 billion from 2000 to 2001 to 2012–2013 [5] and is associated with about $131 billion per year in population-level expenditures [6].
Unhealthy diet, physical inactivity and obesity increase the risk of developing hypertension [7]. Lifestyle change is a key component in the cardiovascular risk management and essential in decreasing blood pressure [810]. Studies evaluating lifestyle modifications such as weight-reducing diets, regular exercise as well as restricted alcohol and salt intake showed positive effects on blood pressure [11]. In a systematic review, Dickinson et al. assessed the effects of the different lifestyle modifications. Improved diet resulted in a mean reduction of systolic blood pressure (SBP) of − 5.0 mmHg (95% CI, − 7.0 to − 3.1), aerobic exercise − 4.6 mmHg (95% CI, − 7.1 to − 2.0), alcohol restriction - 3.8 mmHg (95% CI, − 6.1 to − 1.4) and sodium restriction − 3.6 mmHg (95% CI, − 4.6 to − 2.5) [12]. Healthcare professionals have an important role in supporting patients in achieving such lifestyle alterations to improve blood pressure control. Previous systematic reviews have shown that pharmacist- [13] and nurse- [14] led interventions can be successful in improving blood pressure control, but those studies did not focus on interventions of lifestyle modification. In another systematic review, it was shown that physician-led interventions result in significant weight losses, but this study did not assess hypertension [15]. An overview of effective lifestyle interventions which can be performed by healthcare professionals is lacking. Therefore, the aim of this study was to determine whether healthcare professional-led interventions on lifestyle modifications are effective in lowering blood pressure in patients with hypertension.

Methods

A systematic literature review and meta-analysis following the PRISMA guidelines for reporting was performed [16]. A literature search for studies evaluating interventions on lifestyle modifications in patients with hypertension was conducted.

Inclusion and exclusion criteria

Included studies:
  • Were randomized controlled clinical trials (RCTs);
  • Involved patients with a diagnosis of hypertension or with an elevated blood pressure above 140/90 mmHg or 130/80 for patients with diabetes [17];
  • Evaluated an intervention led by a healthcare professional which consisted of one or more individual consultations on lifestyle modification, health promotion or non-pharmaceutical management, targeting blood pressure.
Excluded studies:
  • Were non-English articles;
  • Interventions performed in group sessions;
  • Consisted of pharmacological interventions only;
  • Interventions that included less than 10 patients in either intervention or control group
Studies which compared two different approaches of lifestyle intervention were not in the scope of this review. These were for example studies which assigned patients assigned to sports activities or diet management. Those studies compared the effects of specific sports or diets rather than investigate effects of the provider-led interventions.
Healthcare professionals were defined as those with extensive knowledge including university-level study leading to the award of a first degree or higher qualification [18], in most cases – physicians, nurses and pharmacists. Studies that included less than 10 patients were excluded as they would be more heterogeneous and a high possibility of selection bias in a small study could occur [19]. Interventions were defined as tailored when the contact with a healthcare professional was intensified or de-intensified, based on the patient’s blood pressure data.

Outcome measures

Outcomes of the review were the difference in systolic and diastolic blood pressure between intervention and control groups, and the difference in the proportion of patients achieving BP control.

Data collection and analysis

The systematic review protocol was created. Search keys for PubMed, Embase and Cinahl were built; additionally, the references of indicated papers were searched. The PubMed search key could be found in the Additional file 1.
The search was carried out on the 18th of May 2020.
Two researchers – I.T. and J.P. – independently reviewed titles, abstracts and full articles. Reviewers separately reviewed the extracted data on number of patients, the duration of intervention and follow-up, intervention components as well as baseline and follow-up blood pressure measurements and discussed the discrepancies. In case of discrepancies, cases were discussed with a third reviewer K.T. If any data required for the analyses was missing in the retrieved articles, the authors were contacted.
Two researchers – I.T. and T.F. – assessed the risk of bias using the Cochrane risk of bias tool [20]. Non-pharmacological interventions may introduce more biases as the participants and personnel cannot always be blinded due to the nature of the interventions. Baseline characteristics of included patients may have an impact on the overall assessment of biases as well. Nine criteria for the assessment of risk of bias were used, including random sequence generation, allocation concealment, similarity of baseline outcome measurements, similarity of baseline characteristics, blinding of outcome assessment, incomplete outcome data, contamination, selective reporting and other biases reported by the investigators. Biases were assigned to one of the three categories – low risk, unclear risk and high risk. Studies having 4 or more criteria scoring high risk/unclear risk were categorized as having an overall high risk of bias.
Meta-analyses by RevMan 5.4 using a random effects analysis model was performed. The mean difference in systolic and diastolic blood pressure between the intervention and the usual care group was calculated, as well as the percentage of patients who achieved BP control in the intervention and the usual care group. The odds ratio for BP control were determined.
To avoid unit-of-analysis errors for cluster-randomized controlled trials (cRCTs) in which incorrect statistical analyses were conducted, an approximate analysis based on inflating standard errors was performed. Before entering data into RevMan the standard error of the effect estimate (from an analysis that does not take clustering into account) was multiplied by the square root of the design effect. The design effect was determined as 1+ (M-1) ICC, where M is the average cluster size and ICC – the intracluster correlation coefficient. The common design effect across the intervention groups was assumed. If the ICC was not available in the published report, the mean ICC from other included cRCTs was used. Sensitivity analyses for RCT comparing the data as presented and taking the intracluster correlation coefficient into account was performed.
If the study included more than two intervention arms and no control or usual care group, the intervention closest to usual care was considered as usual care. If the studies had two treatment arms and a usual care group, only the treatment arm that had lifestyle modification or health promotion provided by health care professional was included into meta-analyses. This approach was chosen in line with recommendations by Cochrane to overcome a unit-of-analysis error [20].
Means and standard deviations from a relevant intervention or a usual care group were pooled. If standard deviation (SD) was not provided in the study report, it was calculated with the “Cochrane collaboration finding standard deviations calculator” from other standard errors or confidence intervals given. If the data was missing or clarification needed the authors were contacted. If it was not possible to obtain SD, the mean SD of the included studies was used.
Heterogeneity according to the approach described in the Cochrane Handbook was assessed [20]. The I2 statistic to assess heterogeneity was used, considering heterogeneity to be statistically significant if the p value was less than 0.05. The interpretation of the I2 statistic was followed, 0–30% might not be important, 30–60% may represent moderate heterogeneity, 50–75% may represent substantial heterogeneity and 75–100% represents considerable heterogeneity. Since it was assumed that clinical and methodological diversity within the studies may occur, it was agreed that I2 value between 30 and 60% represents moderate heterogeneity, and I2 over 60% represents substantial heterogeneity.

Data synthesis and subgroup analysis

Intervention effects for dichotomous data were calculated as odds ratio with the 95% confidence intervals. For continuous data, the mean differences with the 95% confidence intervals were calculated. Extreme outliers were excluded from the analysis, a sensitivity analysis including the outliers was performed.
Several subgroup analyses were carried out as recommended [21]. Subgroup analyses based on place the outcome blood pressure was taken (home or office), the duration of an intervention (under 6 months or longer than 6 months), by the type of healthcare professional and the type of intervention (face to face vs via device and tailored vs not tailored intervention) were performed. In further subgroup analyses the effects in patients with baseline systolic blood pressure under and above 150 mmHg were investigated. Finally, the effects of interventions which included medication adherence tool or antihypertensive medications review were investigated.

Results

The description of studies

Eight thousand seven hundred eighty-one articles were retrieved (Fig. 1).
Thirty-five clinical trials were included in the review. In the studies, 22,715 patients were randomized; the mean age was 58.1 years, 49% were female, 69% used antihypertensive medications. At least 23% of included patients were diagnosed with diabetes.
Of the included studies, 30 were individual randomized controlled trials and 5 were cluster randomized trials. Twenty studies were carried out in the United States [2241], 4 in Europe [4245], 2 in China [46, 47] 1 in Canada [48], Australia [49], Mexico [50], Taiwan [51], Pakistan [52], Thailand [53], South Africa [54], Japan [55] and India [56]. For 20 studies [24, 25, 2729, 3133, 38, 41, 43, 4551, 5356] a follow-up was completed within 6 months, in the remaining studies a follow-up was from 6 to 24 months (Table 1).
Table 1
Summary of included studies. Trial length, number of patients, blood pressure and demographic data pooled from the included studies
 
Study design
Country
Trial length in month
Number of patients included
Proportion of patients under BP control %
Diastolic BP at recruitment, mmHg
Systolic BP at recruitment, mmHg
Patients with diabetes %
Female %
Mean age
Race
Proportion using antihypertensive medication, %
Artinian 2007
RCT
USA
8
387
0
> = 90
> = 140
25.83
64.34
59.65
100% African Americans
70.54
Borenstein 2003
RCT
USA
12
197
0
> = 90
> = 140
13
61
62
32% African Americans
N/A
Bosworth 2009
RCT
USA
24
636
73
di
di
36
66
61
49% African Americans
100
Bosworth 2011
RCT
USA
18
591
59
> 90
> 140
43
8
64
48% white
100
Brennan 2010
RCT
USA
12
638
14
di
di
26
67
55.7
100% African Americans
96
Garcia-Pena 2001
RCT
Mexico
6
718
0
> = 90
> = 160
26
64
70.6
N/A
77
Green 2008
RCT
USA
12
778
0
90–109
140–199
N/A
52.2
59.1
82,8% white
96
Hennessy 2006
cRCT
USA
6
10,696
53.29
di
di
25.48
56.95
62.3
48% Caucasian
66.77
Hunt 2004
RCT
USA
12
604
0
90–99
140–159
15
58
69
90% white
N/A
Hunt 2008
RCT
USA
12
463
0
> = 100
> = 160
25
65
68
N/A
N/A
Johnson 2011
RCT
USA
6
552
0
di
di
43
65
42
91% African Americans
96
Kastarinen 2002
RCT
Finland
24
715
N/A
90–109
140–179
N/A
53
54.3
N/A
52
Lang 1995
cRCT
France
18
129
0
> 90
> 140
N/A
5
43
N/A
19
Lee 2007
RCT
Taiwan
6
202
0
N/A
140–179
N/A
42
71.3
N/A
68
Little 2004
cRCT
USA
1
296
0
> 90
> 160
N/A
44
50
N/A
0
Ma 2014
RCT
China
6
120
N/A
di
di
N/A
50.83
58.76
N/A
100
Magid 2011
RCT
USA
6
338
0
> 90 (80a)
> 140 (130a)
54
35
65.4
65% white
100
Margolis 2013
cRCT
USA
18
450
0
> = 90
> = 140
19.11
44.7
61.1
81.8 white
73.8
McKenney 1973
RCT
USA
5
50
32
> 90
N/A
N/A
76
60
78% African American
N/A
McLean 2008
RCT
Canada
6
227
3
> 80
> 130
100
40
64.95
N/A
66.95
Mehos 2000
RCT
USA
6
36
0
90–109
140–179
19.44
69.44
58.8
77.77 Caucasian
100
Morgado 2011
RCT
Portugal
9
197
33
di
di
18
60
59.5
N/A
100
Roumie 2006
cRCT
USA
6
1827
0
> = 90
> 140
4.02
3
65
N/A
100
Saleem 2015
RCT
Pakistan
9
385
41.8
di
di
N/A
31.2
39
N/A
100
Sookaneknun 2004
RCT
Thailand
6
235
20.42
> = 90
> = 140
44
68
63.2
N/A
N/A
Stewart 2005
RCT
South Africa
6
83
N/A
di
di
N/A
N/A
N/A
N/A
N/A
Tobari 2010
RCT
Japan
6
132
38.63
90–109
140–179
N/A
34
61.65
N/A
94
Tonstad 2007
RCT
Norway
6
49
0
90–99
140–169
N/A
26.53
55
N/A
16.32
Vivian 2002
RCT
USA
6
56
0
> 90
> 140
51
0
64.75
77.4% African American
100
Wakefield 2011
RCT
USA
6
302
N/A
di
di
100
2
68
96% Caucasian
N/A
Wal 2013
RCT
India
6
142
0
> 90
> 140
40.19
55.88
60.06
N/A
N/A
Woollard 1995
RCT
Australia
4.5
166
N/A
di
di
N/A
46.57
58.3
N/A
100
Zabler 2018
RCT
China
6
59
N/A
di
di
N/A
63
53.73
100% African American
100
Zhu 2017
RCT
USA
4
134
0
> = 90
> 140
23.9
50.7
69
N/A
81
Zillich 2005
cRCT
USA
3
125
0
di
di
28
61
65
97.6% white
100
di - inclusion under diagnoses of hypertension, the range of inclusion BP not specified
N/A data not available
a different inclusion blood pressure for diabetes patients
In all the studies, lifestyle modification was addressed. Two interventions were performed in community pharmacies [32, 48] one in pharmacy and primary care [53] all other studies were performed in primary care practices or outpatient centers of hospitals. In 16 studies the advice on dietary/sodium restriction was given [24, 28, 29, 34, 35, 37, 41, 42, 45, 46, 49, 50, 5356]. Twenty studies addressed dietary/weight loss/dietary approaches to stop hypertension (DASH) [23, 24, 27, 31, 3438, 4042, 45, 47, 49, 50, 5356]. Recommendations on alcohol consumption were given in 14 studies [24, 28, 34, 35, 4143, 4547, 49, 53, 55, 56]. Fourteen studies included smoking cessation [23, 24, 31, 3436, 42, 4547, 49, 53, 55, 56]. Exercise/physical activity was recommended in 20 studies [23, 24, 28, 29, 31, 34, 36, 37, 41, 42, 4547, 4951, 5356]. Education on home blood pressure monitoring was provided and home BP devices were given in 13 studies [22, 2426, 28, 31, 32, 3437, 39, 55]. Seven studies included tailored interventions [25, 28, 31, 35, 37, 39, 46].
Healthcare professionals were specifically trained to give the intervention in 13 studies [22, 24, 29, 3638, 4143, 46, 47, 50, 52]. Thirteen studies included a medication review in addition to the lifestyle interventions. Those medication reviews were performed by the interventionist or if needed by a healthcare professional the participant was referred to. In those studies recommendations/changes or referrals for changes on antihypertensive medications or regimens were performed if needed, alongside with the lifestyle modification intervention [23, 25, 26, 2830, 32, 35, 39, 46, 48, 53, 55]. In 11 studies adherence improvement was additionally implemented [23, 27, 28, 30, 41, 44, 47, 5255]. Techniques such as pill count, patient diary, assessment with a questionnaire or data on adherence, obtained from the pharmacy and discussed with the patient, were used. In other studies, medication adherence was emphasized or was not mentioned at all. A summary of components of the interventions is provided in Table 2.
Table 2
Summary of components of the interventions. Intervention components pooled from included studies
 
Intervention specialist
Outcome BP place
Tailored
Face-to face lifestyle management intervention
Specialist training
Components of the lifestyle intervention
Medication change referred or recommended
Education on disease
Lifestyle advice not specified
Dietary (Na restriction)
Dietary/weight loss/DASH
Alcohol consumption
Smoking cessation
Exercise/physical activity
Adherence improvement strategies c
Education on home blood pressure monitoring
Artinian 2007
Nurse
Office
No
No
+
 
+
      
+
 
Borenstein 2003
Team
Office
No
Yes
  
+
 
+
 
+
+
+
 
+
Bosworth 2009
Nurse
Office
No
No
   
+
+
+
+
+
 
+
 
Bosworth 2011
Nurse
Office
Yes
No
 
+
 
+
+
+
+
  
+
+
Brennan 2010
Nurse
Home
No
No
+
+
  
+
 
+
+
 
+
 
Garcia-Pena 2001
Nurse
Home
No
Yes
+
+
+
+
+
  
+
   
Green 2008
Pharmacist
Office
Yes
No
+
  
+
+
  
+
 
+
 
Hennessy 2006
Providera
Office
No
No
+
+
  
+
      
Hunt 2004
Primary care provider
Office
No
No
 
+
+
 
+
    
+
 
Hunt 2008
Team
Office
Yes
Yes
 
+
+
       
+
Johnson 2011
Nurse
Office
No
Yes
+
+
 
+
+
+
 
+
+
  
Kastarinen 2002
Nurse
Office
No
Yes
+
  
+
+
+
+
+
   
Lang 1995
Physician
Office
No
Yes
+
    
+
     
Lee 2007
Nurse
Office
No
Mixed
       
+
   
Little 2004
Nurse
Home
No
Yes
+
+
 
+
+
+
+
+
 
+
 
Ma 2014
Nurse
Office
No
Yes
+
   
+
+
+
+
+
  
Magid 2011
Pharmacist
Office
Yes
No
 
+
+
      
+
+
Margolis 2013
Pharmacist
Office
No
Mixed
 
+
+
      
+
+
McKenney 1973
Pharmacist
Office
No
Yes
 
+
  
+
   
+
  
McLean 2008
Team
Office
No
Yes
 
+
+
       
+
Mehos 2000
Pharmacist
Office
Yes
Mixed
 
+
 
+
 
+
 
+
+
+
+
Morgado 2011
Pharmacist
Office
No
yes
 
+
+
     
+
  
Roumie 2006
Providerb
Office
No
No
+
+
 
+
   
+
  
+
Saleem 2015
Pharmacist
Office
No
Yes
+
+
+
     
+
  
Sookaneknun 2004
Pharmacist
Office
No
Yes
 
+
 
+
+
+
+
+
+
 
+
Stewart 2005
Physician
Office
No
No
   
+
+
  
+
+
  
Tobari 2010
Team
Home/office
No
Yes
 
+
 
+
+
+
+
+
+
+
+
Tonstad 2007
Nurse
Office
No
Yes
   
+
+
+
+
+
   
Vivian 2002
Pharmacist
Office
No
Yes
  
+
     
+
 
+
Wakefield 2011
Nurse
nn
Yes
No
  
+
 
+
 
+
+
 
+
 
Wal 2013
Pharmacist
Office
No
Yes
 
+
 
+
+
+
+
+
   
Woollard 1995
Nurse
Office
No
Yes
   
+
+
+
+
+
   
Zabler 2018
Nurse
Office
No
Mixed
+
+
         
Zhu 2017
Nurse
Office
Yes
Mixed
  
+
 
+
+
+
 
+
 
+
Zillich 2005
Team
Office
No
Yes
 
+
+
      
+
+
Mixed intervention – first visit face to face, following visits by device
a Physicians and nurse practitioners in family medicine, internal medicine or obstetrics-genecology
b Attending physicians, resident physicians, nonphysician clinicians (nurse practitioner or physician assistant)
c Adherence tools focused on patient used: pill count, dairy, assessment with questionnaire at time point visits or data on adherence obtained from data base or pharmacist and discussed with the patient at regular visits
The authors of five studies were contacted to obtain missing outcome data. Four responses were received. One study was excluded from the meta-analyses as the missing data could not be obtained. Thirty-four studies contained sufficient data to be included in the meta-analyses. Twenty two thousand four hundred nineteen patients with mean age of 58.4 years where randomized in those studies. Forty-nine point fourteen percent of patients were female, 69.97% used antihypertensive medications.
The risk of bias of the studies that were included into meta-analyses was evaluated. Nine studies were considered as low in the overall assessment of bias, 25 as high (Fig. 2).
Contamination was possible when healthcare professionals were allocated within the same clinic or practice; in this case the communication between intervention and control professionals as well as patients was possible. In the cluster randomized trials with the allocation by an institution or a practice, this risk was prevented. Other risks provided by the authors were also common. The other risks of biases reported were not taking clustering into account [26, 32, 43], self-selection biases [36] labelling, that might have caused the increased care by a physician [53] only highly motivated [42] or highly educated patients included [37] language literacy [39] real world barriers [41] etc.

Systolic blood pressure

The mean difference of the SBP between the intervention group and the usual care group was − 4.41 mmHg (95% CI, − 5.52 to − 3.30). Patients with SBP higher than 150 mmHg at baseline showed better response to intervention than patients with baseline SBP lower or equal to 150 mmHg. The mean difference SBP was − 5.66 mmHg (95% CI, − 7.61 to − 3.71) and − 3.35 mmHg (95% CI, − 4.43 to − 2.26) compared to the usual care group respectively (P = 0.04) (Fig. 3).
There were no statistically significant differences in the mean reduction of SBP in the sub analysis by the type of a healthcare professional (Fig. 4).
There were also no statistically significant differences in the subgroup analyses by the duration of an intervention, the place of BP measurement, whether the interventions were tailored or not and whether the interventions contained a component addressing medication adherence (Table 3).
Table 3
The overview of subgroup analyses of the effect of interventions on SBP
Subgroups
Mean difference SBP mmHg (95% CI)
P value1
Duration of intervention
6 months and under
Over 6 months
 
−4.34 (−6.13 to −2.54)
−4.58 (−5.94 to −3.22)
P = 0.83
Place of blood pressure measurement
Home
Physician’s office/clinic
 
−2.85 (−4.66 to −1.04)
−4.50 (−5.74 to −3.26)
P = 0.14
Tailored intervention
Tailored
Not tailored
 
−4.40 (−7.19 to −1.60)
−4.37 (−5.58 to −3.15)
P = 0.99
Medication adherence improvement techniques
Used
Not used
 
−4.34 (− 5.91 to − 2.78)
−4.48 (− 6.09, − 2.88)
P = 0.90
Referral for medication change or adjustment
Included
Not included
 
−4.46 (−6.21 to − 2.71)
−4.40 (− 5.85 to − 2.96)
P = 0.96
1 P value shows if the difference in mean difference of SBP between subgroups is statistically significant. E.g., the subgroup difference between interventions that lasted up to 6 months and interventions that lasted over 6 months was not statistically significant, both interventions were effective

Diastolic blood pressure

Measurements of diastolic blood pressure were provided in 32 studies. Analyses of intervention studies showed that DBP decreased by 1.66 mmHg (95% CI, − 2.44 to − 0.88), I2 = 63%. Heterogeneity of the included studies was too high to perform a subgroup meta-analysis.

Blood pressure control

Seventeen studies provided data on the proportion of patients achieving BP control. Fifty-six percent of patients achieved BP control in an intervention group vs 44% in a usual care group, OR = 1.87 (95% CI, 1.51 to 2.31).
Subgroup analyses revealed that better BP control was achieved when the baseline systolic blood pressure was over 150 mmHg (P = 0.04). Subgroup analyses showed no differences in BP control when different intervention methods or components were used (Table 4). We could not perform subgroup analyses on BP control effect by the place of a BP measurement as the final BP was measured at home only in two studies [36, 55].
Table 4
The overview of the effect of interventions on BP control
Subgroups
OR (95% CI)
P value2
Duration of intervention
6 months and under
Over 6 months
 
1.64 (1.24 to 2.16)
2.14 (1.60 to 2.87)
P = 0.19
Baseline systolic blood pressure
Below 150 mmHg
Over 150 mmHg
 
1.51 [1.17, 1.96]
2.27 [1.83, 2.81]
P = 0.02
Healthcare provider
Single (pharmacist, nurse or physician alone)
Team
 
1.96 [1.47, 2.62]
1.81 [1.38, 2.36]
P = 0.68
Tailored intervention
Tailored
Not tailored
 
1.94 (1.16 to 3.25)
1.83 (1.44 to 2.32)
P = 0.84
Medication adherence improvement techniques
Used
Not used
 
2.35 (1.62 to 3.42)
1.65 (1.28 to 2.11)
P = 0.12
Referral for medication change or adjustment
Included
Not included
 
1.77 [1.41, 2.21]
2.06 [1.34, 3.16]
P = 0.54
2P value shows if the difference in OR between subgroups is statistically significant. E.g., patients with the initial SBP over 150 mmHg had a higher chance to achieve the BP under control than patients with the initial SBP assessment under 150 mmHg and the difference was statistically significant

Discussion

Summary

Interventions were effective and helped to achieve 4.41 mmHg decrease of SBP and 1.66 mmHg decrease of DBP. Statistically better SBP results and better BP control were achieved in the studies where baseline SBP was higher than 150 mmHg. Considering that nearly 70% of the patients were already taking medications, the additional SBP lowering by 5 mmHg might be the solution for a better hypertension control. Several reports support the clinical relevance of SBP reduction by 1–5 mmHg. SBP decrease of 1 mmHg reduces the risk of stroke by 5% [57]. Stamler et al. showed that the reduction of SBP by 5 mmHg is associated with a 7% lower risk of all-cause mortality, 9% lower risk of mortality due to coronary heart disease and 14% lower risk of mortality due to stroke [58].
In subgroup analysis, there were no differences in SBP and BP control between tailored and not tailored interventions, the different healthcare professionals performing the intervention and interventions including vs excluding medication review related components. This suggests that none of the features that were investigated had a preeminent impact, but rather the intervention itself. To further investigate the combined effects of lifestyle changes and medication change and adherence management on hypertension, individual patient data would be needed.

Strengths and limitations

This study is the first systematic review on healthcare professional-led lifestyle interventions focusing on individual hypertensive patients.
Only two studies [25, 45] with blood pressure increase after an intervention were found. This might be that studies having a positive outcome were more likely to be published than those reporting negative results. However, sensitivity analysis with outliers showed that the estimate of the overall effect of interventions on BP was similar. As the heterogeneity was expected, the random effects analysis to allow for differences in the treatment effect from study to study was used. The potential sources of heterogeneity were explored by conducting subgroup analyses by the type of clinical trial method, the duration of intervention and the type of a healthcare professional performing the intervention. No difference in effect was found. Moreover, sensitivity analyses accounting for an overall assessment of bias and study size reported similar effects on BP. Causes of heterogeneity could be comorbidities, the number of medications or the age of the patients, but the reasons were not identified, as individual patient data would have been required. Differences in terms of interventions, data collection methods and setting may explain the heterogeneity as well.

Comparison with existing literature

The study results support the idea that the modification of lifestyle is important for lowering blood pressure and managing cardiovascular risk. Results are in line with other systematic reviews on different types of interventions. Internet-based interventions showed to reduce SBP by 3.8 mmHg and DBP by 2.1 mmHg [59] and digital interventions to reduce SPB by 3.74 mmHg and DBP by 2.37 mmHg [60]. Self-monitoring of hypertension was associated with a significant decline in SBP by 3.96 mmHg and DBP by 1.85 mmHg [61].
All international guidelines recommend non-pharmacological approaches in the early stages of hypertension. In the ACC/AHA 2017 guidelines, interventions on lifestyle modifications have an even greater place in the management of hypertensive patients than in the European guidelines. ACC/AHA 2017 guidelines recommend lifestyle modifications to the patients having 130–139/80–89 mmHg blood pressure, reviewing the effects after 3 or 6 months [62]. Although traditionally interventions on lifestyle modifications are the domain of physicians or nurses, pharmacists could perform those interventions as well. This is in line with the developments to extend the traditional role of pharmacists [63, 64].

Implications for research and practice

As the interventions were complex, the intervention component that had the maximum effect on blood pressure was not singled out. This may suggest the opportunity for future research. Individual patient data meta-analysis could explain the effects of interventions on different patients’ groups. Cost effectiveness studies could provide economic assessment of lifestyle interventions.
This systematic review shows that healthcare professional-led interventions on lifestyle modifications lowered elevated blood pressure and a higher percentage of patients had their blood pressure well controlled. The results suggest that healthcare professional-led interventions on lifestyle modifications should be implemented in daily practice. The barriers to implement such interventions include traditional practices and structures; sceptical, stereotypical attitudes from professionals; and factors related to the development of person-centered interventions [65].

Conclusions

Healthcare professional-led interventions were effective. Patients achieved almost 5 mmHg decrease of SBP and more patients achieved BP control. The results suggest that efforts are needed for widespread implementation.

Acknowledgements

Not applicable.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat WHO. Noncommunicable diseases country profiles 2018: WHO; 2018. WHO. Noncommunicable diseases country profiles 2018: WHO; 2018.
3.
Zurück zum Zitat Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics’2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603 Lippincott Williams and Wilkins.PubMedPubMedCentralCrossRef Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics’2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603 Lippincott Williams and Wilkins.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015. JAMA. 2017;317(2):165–82.PubMedCrossRef Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015. JAMA. 2017;317(2):165–82.PubMedCrossRef
5.
Zurück zum Zitat Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical expenditures associated with hypertension in the U.S., 2000–2013. Am J Prev Med. 2017;53(6):S164–71.PubMedPubMedCentralCrossRef Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical expenditures associated with hypertension in the U.S., 2000–2013. Am J Prev Med. 2017;53(6):S164–71.PubMedPubMedCentralCrossRef
6.
7.
Zurück zum Zitat Forouzanfar MH, Afshin A, Alexander LT, Biryukov S, Brauer M, Cercy K, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1659–724.CrossRef Forouzanfar MH, Afshin A, Alexander LT, Biryukov S, Brauer M, Cercy K, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1659–724.CrossRef
8.
Zurück zum Zitat Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41(1):12–85.PubMedCrossRef Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41(1):12–85.PubMedCrossRef
10.
Zurück zum Zitat Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovas JM, Ruilope LM, et al. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2020:1–25 Nature Research. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovas JM, Ruilope LM, et al. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2020:1–25 Nature Research.
11.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81 Oxford University Press.PubMedPubMedCentralCrossRef Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81 Oxford University Press.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Cheema E, Sutcliffe P, Singer DRJ. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78(6):1238–47.PubMedPubMedCentralCrossRef Cheema E, Sutcliffe P, Singer DRJ. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78(6):1238–47.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Clark CE, Smith LFP, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:491 BMJ Publishing Group. Clark CE, Smith LFP, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:491 BMJ Publishing Group.
15.
Zurück zum Zitat Rose SA, Poynter PS, Anderson JW, Noar SM, Conigliaro J. Physician weight loss advice and patient weight loss behavior change: a literature review and meta-analysis of survey data. Int J Obes. 2013;37:118–28 Nature Publishing Group.CrossRef Rose SA, Poynter PS, Anderson JW, Noar SM, Conigliaro J. Physician weight loss advice and patient weight loss behavior change: a literature review and meta-analysis of survey data. Int J Obes. 2013;37:118–28 Nature Publishing Group.CrossRef
17.
Zurück zum Zitat Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701 Oxford University Press. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701 Oxford University Press.
19.
Zurück zum Zitat Inthout J, Ioannidis JPA, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol. 2015;68(8):860–9.PubMedCrossRef Inthout J, Ioannidis JPA, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol. 2015;68(8):860–9.PubMedCrossRef
20.
Zurück zum Zitat Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane, 2020. [Internet]. Available from: www.training.cochrane.org/handbook. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane, 2020. [Internet]. Available from: www.​training.​cochrane.​org/​handbook.
21.
Zurück zum Zitat Jakobsen JC, Wetterslev J, Lange T, Gluud C, et al. Cochrane Database Syst Rev. 2016;3:ED000111 Wiley.PubMed Jakobsen JC, Wetterslev J, Lange T, Gluud C, et al. Cochrane Database Syst Rev. 2016;3:ED000111 Wiley.PubMed
23.
Zurück zum Zitat Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Jackson A, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23(2):209–16.PubMedCrossRef Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Jackson A, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23(2):209–16.PubMedCrossRef
24.
Zurück zum Zitat Little P, Kelly J, Barnett J, Dorward M, Margetts B, Warm D. Randomised controlled factorial trial of dietary advice for patients with a single high blood pressure reading in primary care. Br Med J. 2004;328(7447):1054–7.CrossRef Little P, Kelly J, Barnett J, Dorward M, Margetts B, Warm D. Randomised controlled factorial trial of dietary advice for patients with a single high blood pressure reading in primary care. Br Med J. 2004;328(7447):1054–7.CrossRef
25.
Zurück zum Zitat Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96–103.PubMed Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96–103.PubMed
26.
Zurück zum Zitat Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control a cluster randomized clinical trial. JAMA. 2013;310(1):46–56.PubMedPubMedCentralCrossRef Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control a cluster randomized clinical trial. JAMA. 2013;310(1):46–56.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat McKenney JM, Slining JM, Richard Henderson H, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973;48(5):1104–11.PubMedCrossRef McKenney JM, Slining JM, Richard Henderson H, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973;48(5):1104–11.PubMedCrossRef
28.
Zurück zum Zitat Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):1384–9.PubMedCrossRef Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):1384–9.PubMedCrossRef
29.
Zurück zum Zitat Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med. 2006;145(3):165–75.PubMedCrossRef Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med. 2006;145(3):165–75.PubMedCrossRef
30.
Zurück zum Zitat Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22(12 I):1533–40.PubMedCrossRef Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22(12 I):1533–40.PubMedCrossRef
31.
Zurück zum Zitat Wakefield BJ, Holman JE, Ray A, Scherubel M, Adams MR, Hillis SL, et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: a randomized, controlled trial. Telemed e-Health. 2011;17(4):254–61.CrossRef Wakefield BJ, Holman JE, Ray A, Scherubel M, Adams MR, Hillis SL, et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: a randomized, controlled trial. Telemed e-Health. 2011;17(4):254–61.CrossRef
32.
Zurück zum Zitat Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med. 2005;20(12):1091–6.PubMedPubMedCentralCrossRef Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med. 2005;20(12):1091–6.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Zabler B, Tsai PY, Fendrich M, Cho Y, Taani MH, Schiffman R. Effect of a nurse case management intervention for hypertension self-management in low-income African Americans. Contemp Clin Trials. 2018;71:199–204.PubMedPubMedCentralCrossRef Zabler B, Tsai PY, Fendrich M, Cho Y, Taani MH, Schiffman R. Effect of a nurse case management intervention for hypertension self-management in low-income African Americans. Contemp Clin Trials. 2018;71:199–204.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151(10):687–95.PubMedPubMedCentralCrossRef Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151(10):687–95.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171(13):1173–80.PubMedCrossRef Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171(13):1173–80.PubMedCrossRef
36.
Zurück zum Zitat Brennan T, Spettell C, Villagra V, Ofili E, McMahill-Walraven C, Lowy EJ, et al. Disease management to promote blood pressure control among african americans. Popul Health Manag. 2010;13(2):65–72.PubMedPubMedCentralCrossRef Brennan T, Spettell C, Villagra V, Ofili E, McMahill-Walraven C, Lowy EJ, et al. Disease management to promote blood pressure control among african americans. Popul Health Manag. 2010;13(2):65–72.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299(24):2857–67.PubMedPubMedCentralCrossRef Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299(24):2857–67.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966–72.PubMedPubMedCentralCrossRef Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966–72.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Hunt JS, Siemienczuk J, Touchette D, Payne N. Impact of educational mailing on the blood pressure of primary care patients with mild hypertension. J Gen Intern Med. 2004;19(9):925–30.PubMedPubMedCentralCrossRef Hunt JS, Siemienczuk J, Touchette D, Payne N. Impact of educational mailing on the blood pressure of primary care patients with mild hypertension. J Gen Intern Med. 2004;19(9):925–30.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Johnson W, Shaya FT, Khanna N, Warrington VO, Rose VA, Yan X, et al. The Baltimore partnership to educate and achieve control of hypertension (the BPTEACH trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. J Clin Hypertens. 2011;13(8):563–70.CrossRef Johnson W, Shaya FT, Khanna N, Warrington VO, Rose VA, Yan X, et al. The Baltimore partnership to educate and achieve control of hypertension (the BPTEACH trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. J Clin Hypertens. 2011;13(8):563–70.CrossRef
42.
Zurück zum Zitat Kastarinen MJ, Puska PM, Korhonen MH, Mustonen JN, Salomaa VV, Sundvall JE, et al. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. J Hypertens. 2002;20(12):2505–12.PubMedCrossRef Kastarinen MJ, Puska PM, Korhonen MH, Mustonen JN, Salomaa VV, Sundvall JE, et al. Non-pharmacological treatment of hypertension in primary health care: a 2-year open randomized controlled trial of lifestyle intervention against hypertension in eastern Finland. J Hypertens. 2002;20(12):2505–12.PubMedCrossRef
43.
Zurück zum Zitat Lang T, Nicaud V, Darné B, Rueff B. Improving hypertension control among excessive alcohol drinkers: a randomized controlled trial in France. J Epidemiol Community Health. 1995;49(6):610–6.PubMedPubMedCentralCrossRef Lang T, Nicaud V, Darné B, Rueff B. Improving hypertension control among excessive alcohol drinkers: a randomized controlled trial in France. J Epidemiol Community Health. 1995;49(6):610–6.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.PubMedPubMedCentralCrossRef Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Tonstad S, Alm CS, Sandvik E. Effect of nurse counselling on metabolic risk factors in patients with mild hypertension: a randomised controlled trial. Eur J Cardiovasc Nurs. 2007;6(2):160–4.PubMedCrossRef Tonstad S, Alm CS, Sandvik E. Effect of nurse counselling on metabolic risk factors in patients with mild hypertension: a randomised controlled trial. Eur J Cardiovasc Nurs. 2007;6(2):160–4.PubMedCrossRef
46.
Zurück zum Zitat Zhu X, Wong FKY, Wu CLH. Development and evaluation of a nurse-led hypertension management model: a randomized controlled trial. Int J Nurs Stud. 2018;77:171–8.PubMedCrossRef Zhu X, Wong FKY, Wu CLH. Development and evaluation of a nurse-led hypertension management model: a randomized controlled trial. Int J Nurs Stud. 2018;77:171–8.PubMedCrossRef
47.
Zurück zum Zitat Ma C, Zhou Y, Zhou W, Huang C. Evaluation of the effect of motivational interviewing counselling on hypertension care. Patient Educ Couns. 2014;95(2):231–7.PubMedCrossRef Ma C, Zhou Y, Zhou W, Huang C. Evaluation of the effect of motivational interviewing counselling on hypertension care. Patient Educ Couns. 2014;95(2):231–7.PubMedCrossRef
48.
Zurück zum Zitat McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168(21):2355–61.PubMedCrossRef McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168(21):2355–61.PubMedCrossRef
49.
Zurück zum Zitat Woollard J, Beilin L, Lord T, Puddey I, MacAdam D, Rouse I. A controlled trial of nurse counselling on lifestyle change for hypertensives treated in general practice: preliminary results. Clin Exp Pharmacol Physiol. 1995;22(6–7):466–8.PubMedCrossRef Woollard J, Beilin L, Lord T, Puddey I, MacAdam D, Rouse I. A controlled trial of nurse counselling on lifestyle change for hypertensives treated in general practice: preliminary results. Clin Exp Pharmacol Physiol. 1995;22(6–7):466–8.PubMedCrossRef
50.
Zurück zum Zitat Garcia-Peña C, Thorogood M, Armstrong B, Reyes-Frausto S, Muñoz O. Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. Int J Epidemiol. 2001;30(6):1485–91.PubMedCrossRef Garcia-Peña C, Thorogood M, Armstrong B, Reyes-Frausto S, Muñoz O. Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. Int J Epidemiol. 2001;30(6):1485–91.PubMedCrossRef
51.
Zurück zum Zitat Lee LL, Arthur A, Avis M. Evaluating a community-based walking intervention for hypertensive older people in Taiwan: a randomized controlled trial. Prev Med. 2007;44(2):160–6.PubMedCrossRef Lee LL, Arthur A, Avis M. Evaluating a community-based walking intervention for hypertensive older people in Taiwan: a randomized controlled trial. Prev Med. 2007;44(2):160–6.PubMedCrossRef
52.
Zurück zum Zitat Saleem F, Hassali MA, Shafie AA, Ul Haq N, Farooqui M, Aljadhay H, et al. Pharmacist intervention in improving hypertension-related knowledge, treatment medication adherence and health-related quality of life: a non-clinical randomized controlled trial. Health Expect. 2015;18(5):1270–81.PubMedCrossRef Saleem F, Hassali MA, Shafie AA, Ul Haq N, Farooqui M, Aljadhay H, et al. Pharmacist intervention in improving hypertension-related knowledge, treatment medication adherence and health-related quality of life: a non-clinical randomized controlled trial. Health Expect. 2015;18(5):1270–81.PubMedCrossRef
53.
Zurück zum Zitat Sookaneknun P, Richards RME, Sanguansermsri J, Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother. 2004;38:2023–8.PubMedCrossRef Sookaneknun P, Richards RME, Sanguansermsri J, Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother. 2004;38:2023–8.PubMedCrossRef
54.
Zurück zum Zitat Stewart A, Noakes T, Eales C, Shepard K, Becker P, Veriawa Y. Adherence to cardiovascular risk factor modification in patients with hypertension. Cardiovasc J S Afr. 2005;16(2):102–7.PubMed Stewart A, Noakes T, Eales C, Shepard K, Becker P, Veriawa Y. Adherence to cardiovascular risk factor modification in patients with hypertension. Cardiovasc J S Afr. 2005;16(2):102–7.PubMed
55.
Zurück zum Zitat Tobari H, Arimoto T, Shimojo N, Yuhara K, Noda H, Yamagishi K, et al. Physician-pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. Am J Hypertens. 2010;23(10):1144–52.PubMedCrossRef Tobari H, Arimoto T, Shimojo N, Yuhara K, Noda H, Yamagishi K, et al. Physician-pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. Am J Hypertens. 2010;23(10):1144–52.PubMedCrossRef
56.
Zurück zum Zitat Wal P, Wal A, Bhandari A, Pandey U, Rai A. Pharmacist involvement in the patient care improves outcome in hypertension patients. J Res Pharm Pract. 2013;2(3):123.PubMedPubMedCentralCrossRef Wal P, Wal A, Bhandari A, Pandey U, Rai A. Pharmacist involvement in the patient care improves outcome in hypertension patients. J Res Pharm Pract. 2013;2(3):123.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public health and medical care implications. Hypertension. 1989;14(5):570–7.PubMedCrossRef Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public health and medical care implications. Hypertension. 1989;14(5):570–7.PubMedCrossRef
59.
Zurück zum Zitat Liu S, Dunford SD, Leung YW, Brooks D, Thomas SG, Eysenbach G, et al. Reducing blood pressure with internet-based interventions: a meta-analysis. Can J Cardiol. 2013;29:613–21 Canadian Journal of Cardiology.PubMedCrossRef Liu S, Dunford SD, Leung YW, Brooks D, Thomas SG, Eysenbach G, et al. Reducing blood pressure with internet-based interventions: a meta-analysis. Can J Cardiol. 2013;29:613–21 Canadian Journal of Cardiology.PubMedCrossRef
60.
Zurück zum Zitat McLean G, Band R, Saunderson K, Hanlon P, Murray E, Little P, et al. Digital interventions to promote self-management in adults with hypertension systematic review and meta-analysis. J Hypertens. 2016;34:600–12 Lippincott Williams and Wilkins.PubMedPubMedCentralCrossRef McLean G, Band R, Saunderson K, Hanlon P, Murray E, Little P, et al. Digital interventions to promote self-management in adults with hypertension systematic review and meta-analysis. J Hypertens. 2016;34:600–12 Lippincott Williams and Wilkins.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Li R, Liang N, Bu F, Hesketh T. The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis. J Med Internet Res. 2020;22:e17776. Li R, Liang N, Bu F, Hesketh T. The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis. J Med Internet Res. 2020;22:e17776.
62.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:E13–115 Lippincott Williams and Wilkins.PubMed Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:E13–115 Lippincott Williams and Wilkins.PubMed
63.
Zurück zum Zitat Mes MA, Katzer CB, Chan AHY, Wileman V, Taylor SJC, Horne R. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. Eur Respir J. 2018;52 European Respiratory Society. Mes MA, Katzer CB, Chan AHY, Wileman V, Taylor SJC, Horne R. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. Eur Respir J. 2018;52 European Respiratory Society.
64.
Zurück zum Zitat van Eikenhorst L, Taxis K, van Dijk L, de Gier H. Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis. Front Pharmacol. 2017;8 Frontiers Media S.A. van Eikenhorst L, Taxis K, van Dijk L, de Gier H. Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis. Front Pharmacol. 2017;8 Frontiers Media S.A.
Metadaten
Titel
Healthcare professional-led interventions on lifestyle modifications for hypertensive patients – a systematic review and meta-analysis
verfasst von
Indre Treciokiene
Maarten Postma
Thang Nguyen
Tanja Fens
Jurgis Petkevicius
Raimondas Kubilius
Jolanta Gulbinovic
Katja Taxis
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Primary Care / Ausgabe 1/2021
Elektronische ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-021-01421-z

Weitere Artikel der Ausgabe 1/2021

BMC Primary Care 1/2021 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Metformin rückt in den Hintergrund

24.04.2024 DGIM 2024 Kongressbericht

Es hat sich über Jahrzehnte klinisch bewährt. Doch wo harte Endpunkte zählen, ist Metformin als alleinige Erstlinientherapie nicht mehr zeitgemäß.

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

24.04.2024 DGIM 2024 Kongressbericht

Unerkannte Herzmuskelentzündungen infolge einer Virusinfektion führen immer wieder dazu, dass junge, gesunde Menschen plötzlich beim Sport einen Herzstillstand bekommen. Gerade milde Herzbeteiligungen sind oft schwer zu diagnostizieren – speziell bei Leistungssportlern. 

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.